Skip to Main Content

Ian Read blinked.

In an unexpected about-face, Pfizer agreed to defer substantial price hikes that went into effect just last week on more than 40 medicines after its chief executive spoke with President Trump, who is under increasing pressure to take action to lower the cost of prescription drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I don’t know why Pfizer agreed to hold the price hikes. It’s an irony that who charges $200,000 to become a member of his club saying that Pfizer and other drug companies should be ashamed.

  • Is this the new dance craze of summer 2018?
    “The political two-step”

    I think Trump must have talked aggressive action against pharma pricing strategy after the missed 2-week deadline following his veiled threat about
    ‘voluntary action, or else’ (regulatory heavy boots).

Comments are closed.